Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Regorafenib in Combination With Oral Methotrexate for KRAS Mutated Non-Small Cell Lung Cancer (NSCLC)

NCT03520842 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT03520842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03520842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Regorafenib in Combination With Oral Methotrexate for KRAS Mutated Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Completed
Start date
August 14, 2018
Completion date
June 15, 2022
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kras gene mutation, metastatic malignant neoplasm in the brain, recurrent non-small cell lung carcinoma, stage iv non-small cell lung cancer ajcc v7